Leukaemia Trial Service Unit Special Project Grant

在过去的几十年里，白血病的治疗取得了一些惊人的进展，但大多数的改善，包括被诊断患有白血病的儿童，都是一系列小步骤的结果。在过去的30年里，CTSU一直处于英国和国际上这项工作的最前沿。该股通过帮助设计随机试验和有效地进行这些试验，提供了关于不同类型白血病治疗效果的可靠证据。此外，通过收集和组合来自全球许多不同研究小组的数百项试验中每名患者的数据（荟萃分析），CTSU已经能够确定这些治疗的益处和危害在不同类型的患者之间的差异。本申请是为了使这项工作得以继续。在某些情况下，患者的前景仍然很差，需要测试新的治疗方法。在其他情况下，需要确定是否可以减轻治疗负担。儿童白血病就是这种情况，新技术可以识别出可能不需要目前的全面标准治疗的低风险儿童。试验是单独资助的，但这笔资金不支持调查益处是否持久以及是否有任何晚期不良反应所需的长期随访。核心资金对于支持未来试验所需的规划工作和进行额外分析，如确定新的风险组定义，也至关重要。荟萃分析需要持续的资金，以维持已进行试验的研究小组的合作小组，他们分享数据并帮助解释结果。

There have been a few striking advances in the treatment of leukaemia in the last few decades but most of the improvements, including that seen for children diagnosed with leukaemia, have been the result of an incremental series of small steps. Over the past 30 years, CTSU have been at the forefront of this work in the UK and internationally. The Unit has provided reliable evidence on the effectiveness of treatments in the different types of leukaemia by helping to design randomised trials and by running these trials efficiently. Furthermore by collecting and combining data on each patient in hundreds of trials from many different research groups around worldwide (meta-analysis), CTSU have been able to determine how the benefits and harms of these treatment vary between different types of patient. This application is to allow the continuation of this work. In some cases where the outlook for patients remains poor, there are new treatments which need testing. In others there is a need to determine whether the burden of treatment can be reduced. This is the case in childhood leukaemia, where new techniques allow the identification of low risk children who may not require the current full standard therapy. Trials are separately funded, but this funding does not support the long-term follow-up required to investigate whether benefits are lasting and whether there are any late adverse effects. Core funding is also vital to support the planning work that is needed for future trials and to perform additional analyses, such as the determination of new risk group definitions. The meta-analyses require continuing funding in order to maintain the collaborative groups of research groups that have run trials, who share their data and help interpret the results.